Direct Intracranial Venous Stenting Evaluation in Patients With Idiopathic INtracranial Hypertension in the Early Phase

Status: Recruiting
Location: See all (3) locations...
Intervention Type: Device, Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This study is aimed at patients suffering from recently discovered intracranial hypertension, caracterized by visual loss, chronic headache and/or tinnitus. The goal is to evaluate if stenting of a specific vein in the brain could decrease the hypertension and improve associated symptoms. Patients will be randomly assigned in either best medical care group (recommended medication associated with weight loss) or interventional group (best medical car + stenting of the specific vein) and will undergo specific follow-up visits after 1, 3 and 12 months.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Subject is ≥ 18 years old at inclusion.

• Subject with definite new diagnosis (˂ 3 months) of IIH satisfying the modified Dandy criteria (A to E)

• Subject with intracranial TVS stenosis on dominant transverse sinus and hypoplastic contralateral one (or bilateral TVS stenosis) diagnosed on MRI

• Normal MRI findings excepted intracranial TVS stenosis or IIH related abnormalities

• Subject with ophthalmologic IIH symptoms and signs (RNFL ≥ 130 µm, Frisen score ≥ 2, and absence of differential diagnostic)

• Subject without macular ganglion cells atrophy seen on OCT

• Patient having received information about data collection and having signed and dated an Informed Consent Form

• Subjects must be able to attend all scheduled visits and to comply with all trial procedures

• Subjects must be covered by public health insurance

Locations
Other Locations
France
CHU de Montpellier Hôpital Gui de Chauliac
RECRUITING
Montpellier
CHU de REIMS
NOT_YET_RECRUITING
Reims
CHU de Toulouse
NOT_YET_RECRUITING
Toulouse
Contact Information
Primary
Anne DUCROS, MD, PhD
a-ducros@chu-montpellier.fr
+33 467 339 469
Backup
Fédérico CAGNAZZO, MD, PhD
f-cagnazzo@chu-montpellier.fr
+33 467 337 532
Time Frame
Start Date: 2025-09-19
Estimated Completion Date: 2029-04-30
Participants
Target number of participants: 114
Treatments
Active_comparator: best medical care
Acetazolamide and recommended weight loss
Experimental: Experimental (stenting, neuro-radiological intervention)
Stenting of the tranverse sinus vein
Sponsors
Collaborators: Ministère de la Santé
Leads: University Hospital, Montpellier

This content was sourced from clinicaltrials.gov